Our pipeline is composed of IP protected, first-in-class potential assets of novel medicines for significant unmet need, developed via in-house R&D and partnerships through in-license and collaboration with global pharmaceutical and biotech companies. We focus on neurodegenerative and neurological injury disorders by enhancing neuroprotection/repair and controlling neuroinflammation.